Coeptis Therapeutics Shares Rally 59% In May, Here’s Why The Increase Is An Expected Precursor To More ($COEP)
Coeptis Therapeutics (NasdaqGM: COEP) shares surged 59% in May, closing the month at $1.90 and with its intra-month high of $2.19 focused in its crosshairs. Incidentally, that mark is more than a high reached in May; it's a level not closed at since November 2022. While that supports the bullish trend, here's the better news for those just now getting introduced to COEP; the move is no coincidence. On the contrary, investors have plenty of reasons to be bullish on the Coeptis story, particularly for showing its ability to find accretive ways to support and accelerate its mission of developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. (*share price on 5/31/23, Yahoo! Finance, 4:00 PM EST)
And more than investors are giving COEP the attention it deserves. COEP recently announced that research involving its SNAP-CAR technology was detailed in a peer-reviewed article in Nature Communications. SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors. More specifically, the coverage described key advances in antigen receptor design that can be instrumental in developing "universal" receptor systems for diverse programming of cell behaviors using covalent chemistry. Further, it was concluded that these systems have the potential for clinical application and biotechnological utility by allowing researchers to rapidly screen CAR and synNotch antibody candidates and rewire and activate cellular programs in response to particular antibody-antigen interactions.
Indeed, pioneering advances in the bio-pharmaceutical space do come with perks. One is industry attention, which they scored with the peer-reviewed publication. But another one, sometimes considered more valuable for biotech, is earning the attention of investors. After all, even with supporting data, the best of science can only get to the FDA approval finish line with cash behind it. Investors, institutional and retail, are instrumental in fueling those approval ambitions.
In that regard, Coeptis is worthy of the interest...and investment. Why? Because COEP isn't defined by a single headline or publication inclusion. Instead, the value inherent to COEP is better reflected as a sum of its parts consideration. And factoring the several initiatives that can enable them to grow bigger faster, current share prices appear to miss fair value. In other words, the Coeptis stock price may present a compelling value investment opportunity.
Peer Recognition Is Validating A Major Initiative
That's not an overly optimistic presumption, especially noting the particulars published in Nature Communications. Notably, the review highlighted research showing critical advances in antigen receptor design, including creating a universal adaptor synNotch system and a universal CAR system that acts through self-labeling enzyme chemistry. That's more than an important measure; it's a potential breakthrough in programmable antigen targeting. Why is that important?
Because research indicates and supports that these 'universal' receptor systems, where receptor specificity can be directed post-translationally through covalent attachment of a co-administered antibody, potentially allow for one population of T cells to target multiple tumor antigens. That enables the development of cell therapies for a wide range of cancers, including hematologic and solid tumors. Furthermore, it supports the thesis that SNAP-CAR can be a powerful technology holding the potential to be engineered to address other cancers, including HER2-expressing cancer, which COEP is targeting as its potential first-in-human clinical development program. Still, while a sure value driver, there's more to support the bullish proposition.
In April, COEP announced entering a binding term sheet with Deverra Therapeutics, Inc. that provides exclusivity until August 31, 2023, to negotiate toward acquiring or licensing assets from Deverra Therapeutics, specifically those related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.
If the transaction is finalized, it will provide Coeptis with, among other assets, exclusive rights to two FDA-approved Investigational New Drug (IND) applications and two Phase 1 clinical trials (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. Additionally, Coeptis would gain access to a highly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost-effective, on-demand cell therapies to a broad patient population. Deverra expects Phase I clinical trial data from its AML study to be complete during 2H 2023.
Creating Value Through Expanding Clinical Interests
Here's more good news: According to its release, the finalized transaction would significantly expand and enhance Coeptis' technology portfolio with a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data that would also enable aligning its development ambitions with leading cell and gene therapy experts. That's not all. Investors appreciate diversification, and this deal checks that box. COEP noted that adding these clinical and pre-clinical immune effector cell programs would significantly diversify its R&D capabilities and strengthen clinical pipeline assets with multiple novel approaches to combination cellular immunotherapy not yet achieved by others.
Furthermore, the inherent capabilities of the allogeneic cell therapy platform could open new pathways for Coeptis to expand its cell-based therapies beyond autologous CAR T. In fact, COEP management noted in its release that they are "excited about the possibility of exploring the application of both the SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells. The NK and macrophage (MAC) immune effector cell generation from Deverra's platform combined with Coeptis' target specific CARs has the potential to result in development of allogeneic NK and MAC cell therapies." The excitement is warranted.
Deverra's allogeneic cell therapy platform has been used clinically since 2006, with substantial and promising clinical and safety data recorded. While that's valuable, so is the platform showing the capability to provide extreme flexibility and optionality in generating and modifying multiple distinct immune effector cell types from a single platform. Both companies believe this bringing together their established platforms could generate first-in-class allogeneic cell therapies to treat a wide range of life-threatening disorders in a cost-effective and clinically accessible way. Indeed, that's a potentially massive value driver and a near-term one at that.
There's still more intrinsic and inherent firepower contributing to the bullish thesis.
Partnerships Are Expediting Developing Much-Needed Therapeutics
Development programs with other companies put additional milestones in the crosshairs, including progress made with Deverra in evaluating an allogeneic stem cell platform and DVX201, an unmodified natural killer (NK) cell therapy in Phase 1 clinical trials, a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and know-how related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet.
While the science, and especially the describing language, can be complicated, the COEP strategy isn't. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. In other words, COEP is putting in play multiple shots on goal to bring better therapeutics to market and create what could be enormous shareholder value.
Part of that can come through the exclusive option agreements with VyGen-Bio, Inc., involving technologies designed to improve the treatment of CD38-related cancers. For its part, Coeptis will assist VyGen-Bio in its efforts to develop and commercialize CD38-GEAR-NK, a pre-clinical in vitro proof of concept product designed to protect CD38+ NK cells from destruction by antiCD38 mAbs. They will also contribute to developing a CD38-Diagnostic, a discovery-stage product intended to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
There's another value driver. Coeptis currently has a 50% (which could scale down to 25%) revenue stream interest and co-development rights for CD38-GEAR-NK and a 50% revenue stream interest related to CD38-Diagnostic from VyGen-Bio. Coeptis is entitled to receive future revenue from both products.
Multiple Shots On Significant Rev-Gen Goals
Factoring everything in play, the most prudent way to appraise COEP is on a sum of its parts calculation. That model supports appreciably higher share prices, even well above its current level despite its massive May run. Still, that's not to say that COEP isn't worthy of significant appreciation on its parts, either. They are, with substantial intrinsic and inherent value, related to several working programs supporting that proposition. Here's the good news for COEP and its investors.
The trend lately indicates that investors are starting to recognize and seize on a window of opportunity. Understanding how the pharmaceutical sector works they are timely. In Coeptis' case, its cell and gene therapies are more than promising; they have the potential to "disrupt" current treatment paradigms. And precedent shows that larger pharma companies routinely acquire early-stage development assets in this sector.
In fact, Big Pharma like Johnson & Johnson (NYSE: JNJ), Pfizer (NYSE: PFE), and Bristol Myers Squibb (NYSE: BMY) have essentially abandoned in-house development, instead acquiring promising assets like the ones in COEP's arsenal to advance their own clinical ambitions. Simply stated, the gap between Coeptis Therapeutics' share price, considering the intrinsic and inherent potential of its several interests, may be too wide to ignore. Not only for investors but also for potential acquirers.
And with analysts covering Coeptis Therapeutics modeling for $5.00 a share and providing the evidence to justify the forecast, the best proposition for either may be to act on the opportunity while the value window is opened.
Disclaimers: Shore Thing Media, LLC. (STM, Llc.) is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. STM, LLC has been compensated up to five-thousand-dollars cash via wire transfer by a third party to produce and syndicate content for Coeptis Therapeutics, Inc. for a period of two weeks ending on May 11, 2023. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: STM, LLC.
Contact Person: Michael Thomas
Country: United States